

March 30, 2022



# CytoDyn to Hold Webcast to Provide Company Update

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) --**CytoDyn Inc. (OTCQB: CYDY)** ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022.

Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.

**Date:** Thursday, March 31, 2022

**Time:** 5:30 am PT / 8:30 am ET

**Access:** <https://services.choruscall.com/mediaframe/webcast.html?webcastid=v9IRoWUq>

**Questions:** Prior to the webcast, questions can be submitted online to [ir@cytodyn.com](mailto:ir@cytodyn.com)

This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until April 30, 2022.

## CONTACTS

### Investors:

Cristina De Leon  
Office: 360.980.8524  
[ir@cytodyn.com](mailto:ir@cytodyn.com)

### Media:

Dan Zacchei / Joe Germani  
Sloane & Company  
[dzacchei@sloanep.com](mailto:dzacchei@sloanep.com) / [jgermani@sloanep.com](mailto:jgermani@sloanep.com)